Key result
Continuation of aspirin therapy had no significant effect on bleeding volume compared to placebo in patients undergoing skin tumor surgery (median 30 ml in both groups, p=0.107).
Why the study?
Does continuation of aspirin therapy increase bleeding complications in skin cancer patients undergoing surgery?
RCT (n=70)
Double-blind
Block randomization
Does continuation of aspirin therapy increase bleeding complications in skin cancer patients undergoing surgery?
Answers are grounded in this paper and cite their sources.
Supports continuing aspirin in skin tumor surgery; extends RCT evidence for perioperative management in low-bleeding-risk procedures.
UNLABELLED: ᅟ: We investigated the occurrence of bleeding complications in patients who underwent skin tumor surgery and compared it between Aspirin users and a placebo control group. In this double blind randomized controlled trial, 32 patients who continued taking aspirin (intervention group) and 38 patients who stopped taking Aspirin (placebo group) before surgery were compared in terms of intraoprative and postoperative bleeding problems, hematoma and local signs of coagulopathy. There was no statistically significant difference in intraoprative bleeding between the study groups (P = 0.107). We concluded that continuation of Aspirin therapy had no significant effect on bleeding complications in patients who underwent skin tumor surgery. TRIAL REGISTRATION: IRCT201602049768N5 Flow chart of the study process and its final finding.
No takes yet. Share an insight, caveat, or question.
Engheta et al. (2016) conducted an RCT in Skin tumors (n=70). Aspirin vs. Placebo was evaluated on Volume of bleeding within and early after surgery (ml) (p=0.107). Continuation of aspirin therapy had no significant effect on bleeding volume compared to placebo in patients undergoing skin tumor surgery (median 30 ml in both groups, p=0.107).
Synapse has enriched 10 related papers. Consider them for comparative context: